The Wharton School alumnus and experienced chief financial officer Keith A. Goldan will stick around in Chester County in the wake of a major deal between his just-acquired former employer, Nupathe of Malvern, and Israeli multinational drug company Teva Pharmaceutical Industries.

Goldan has now been appointed senior vice president and CFO for Exton gene therapy developer Fibrocell Science. Prior to Nupathe, he drew from his now-20 years of experience while serving as CFO and board member for another Malvern health care company, the med tech firm PuriCore.

“Keith has an exemplary track record of financial leadership and in creating shareholder value in companies ranging from early-stage through sales growth,” Fibrocell Chairman and CEO David Pernock said in an announcement this week. “He will be a valued member of our leadership team as we continue to rapidly advance our pipeline and execute our strategies to take Fibrocell to the next stage.”

The firm is developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs.

“Fibrocell is on the leading edge of science to deliver personalized biologics to patients facing rare skin and connective tissue diseases,” Goldan said. “The company is poised for growth, and as we progress our therapeutics toward approval and commercialization, I am excited to be a part of the team driving to deliver both medical breakthroughs to patients who have poor therapeutic options and long-term value to our shareholders.”